In a Perspective, Stephen Tang and Samuel Sternberg discuss retroelement-based gene editing as a safer alternative to CRISPR-Cas approaches.
IGEA and RBCARE2023 signed to combine their businesses – Biotech Investments
IGEA Pharma N.V. / Key word(s): Agreement/Agreement 03-Oct-2023 / 23:55 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is